Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities

NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities

http://www.reportlinker.com/p01009664/Global-Markets-for-Treatments-of-Dementia-and-Movement-Disorders----Focus-on-Progressive-Dementia-with-Other-Neurological-Abnormalities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

INTRODUCTION

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders. The key objective is to present a comprehensive analysis and the future direction of the market as it shapes drug and therapy development.

This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders. Market gains, setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.

A detailed analysis of the structure of the syndromes of dementia and movement disorder industry has been conducted. Revenues are broken down by neurodegenerative disease and primary clinical/pathological feature. Sales figures are estimated for the five-year period from 2012 through 2017.

Applications for syndromes of dementia and movement disorder treatments, or therapeutic technologies, are also discussed separately in the report, with an emphasis on small molecule and monoclonal antibodies technology. The report also covers significant patents and their allotment in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.

R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study contributes to the areas of market growth in treatments for Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease, corticobasal ganglionic degeneration, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.

METHODOLOGY

BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors' technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this study is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy—An Enduring Market; Advanced Drug Delivery Systems—Technologies and Global Markets; Orthopedic Drugs, Implants and Devices—Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry—The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging—Global Markets; Chiral Technology—Global Markets; Autacoids and Related Drugs—Technologies and Global Markets; Contraceptives—Technologies and Global Markets; Liver Disease Treatments—The Global Market; Hormone Replacement Therapies and Other Hormone Therapies—Global Markets; Cardiovascular Medicine—Diagnostics, Drugs and Devices; and Cancer Therapies ? Technologies and Global Markets.

The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master's degree in biophysics. She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 1

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

CONTRIBUTIONS OF THE STUDY AND FOR WHOM 1

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 2

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 EXECUTIVE SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 6

CHAPTER 3 OVERVIEW 8

THE BRAIN 8

CEREBRAL CORTEX 8

BRAIN STEM 9

SPINAL CORD 10

NEUROTRANSMITTERS 11

CLASSIFICATION OF NEURODEGENERATIVE DISORDERS 11

TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY

PRIMARY CLINICAL/PATHOLOGICAL FEATURE 11

NEURODEGENERATIVE DISORDERS 12

ALZHEIMER'S DISEASE 12

LEWY BODY DEMENTIA 12

PICK'S DISEASE 13

HUNTINGTON'S DISEASE 13

CORTICAL BASAL GANGLIONIC DEGENERATION 13

PARKINSON'S DISEASE 14

MULTIPLE SYSTEM ATROPHY 14

PROGRESSIVE SUPRANUCLEAR PALSY 14

HALLERVORDEN-SPATZ DISEASE 15

DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS 15

DIAGNOSTIC TESTS FOR PARKINSON'S 15

DIAGNOSTIC TESTS FOR ALZHEIMER'S 16

DIAGNOSTIC TESTS FOR PICK'S DISEASE 16

DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY 16

DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY 16

DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION 17

DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA 17

DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE 17

CHAPTER 4 REGULATORY ASPECTS 19

INTRODUCTION 19

DRUG APPROVALS 19

TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012 20

TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS 22

TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012 22

TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, 2010 TO MARCH 2012 23

REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDER PRODUCTS 23

CHAPTER 5 NEW DEVELOPMENTS 25

TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2012 25

TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2011 30

TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2010 39

CHAPTER 6 GLOBAL MARKETS 45

MARKETS BY CLINICAL/PATHOLOGICAL FEATURE 45

MARKET OVERVIEW 45

MARKET REVENUES 46

TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 46

FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 47

MARKET SHARE 47

TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT

NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47

FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT

NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47

MARKET BY DISEASE TYPE 48

MARKET OVERVIEW 49

MARKET REVENUES 50

TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR

NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS) 50

FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR

NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS) 50

MARKET SHARE 51

TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%) 51

FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%) 52

MARKET BY REGION 52

MARKET OVERVIEW 52

MARKET REVENUE 53

TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS) 53

FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS) 53

MARKET SHARE 54

TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54

FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54

MARKETS BY TECHNOLOGY 54

MARKET OVERVIEW 55

MARKET REVENUE 55

TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 56

FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 56

MARKET SHARE 56

TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57

FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57

CHAPTER 7 MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER

NEUROLOGICAL ABNORMALITIES 59

MARKET BY DISEASE TYPE 59

HUNTINGTON'S DISEASE 59

CORTICOBASAL GANGLIONIC DEGENERATION 60

MARKET OVERVIEW 60

TABLE 17 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S

DISEASE 61

MARKET REVENUE 62

TABLE 18 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 ($

MILLIONS)

62

FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 ($

MILLIONS)

63

MARKET SHARE 63

TABLE 19 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63

FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63

MARKET BY REGION 64

MARKET OVERVIEW 64

TABLE 20 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 ($ MILLIONS) 65

FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 ($ MILLIONS) 65

MARKET SHARE 66

TABLE 21 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66

FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66

REGIONAL MARKETS BY DISEASE TYPE 66

HUNTINGTON’S DISEASE 66

TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE

BY REGION, THROUGH 2017 ($ MILLIONS) 67

FIGURE 13 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY

REGION, 2010-2017 ($ MILLIONS) 67

CORTICOBASAL GANGLIONIC DEGENERATION 67

TABLE 23 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC

DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68

FIGURE 14 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC

DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68

MARKET BY TECHNOLOGY 68

SMALL MOLECULES 69

MONOCLONAL ANTIBODIES 70

OTHERS 70

Stem Cells 70

Biomarkers 71

MARKET OVERVIEW 72

MARKET REVENUE 73

TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 ($

MILLIONS)

73

FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 74

MARKET SHARE 74

TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74

FIGURE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74

INDUSTRY STRUCTURE 75

LEADING MANUFACTURERS OF DRUGS USED TO TREAT HUNTINGTON’S

DISEASE 75

TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT

HUNTINGTONâ??S DISEASE 75

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

HUNTINGTON’S DISEASE 78

TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO

TREAT HUNTINGTON'S DISEASE, 2011 (%) 78

FIGURE 17 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR

USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%) 79

LEADING MANUFACTURERS OF DRUGS USED TO TREAT CORTICOBASAL

GANGLIONIC DEGENERATION 79

TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT

HUNTINGTON'S DISEASE 79

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

CORTICOBASAL GANGLIONIC DEGENERATION 81

TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO

TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81

FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT

CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81

CHAPTER 8 PATENT ANALYSIS 84

PATENTS ISSUED BY YEAR 84

TABLE 30 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.) 85

FIGURE 19 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.) 85

FIGURE 20 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%) 86

PATENTS BY DISEASE CATEGORY 86

TABLE 31 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86

FIGURE 21 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86

PATENTS BY DISEASE TYPE 87

SYNDROMES OF DEMENTIA 87

TABLE 32 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012

(NO.)

87

FIGURE 22 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY

CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.) 88

MOVEMENT DISORDER SYNDROMES 88

TABLE 33 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89

FIGURE 23 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89

PATENTS BY COUNTRY 89

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) 89

TABLE 34 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 90

FIGURE 24 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 91

TABLE 35 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY

PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 91

MOVEMENT DISORDER SYNDROMES 92

TABLE 36 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 92

FIGURE 25 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 93

TABLE 37 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER

SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 94

PATENTS BY COMPANY 94

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) 94

TABLE 38 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.) 96

MOVEMENT DISORDER SYNDROMES 100

TABLE 39 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY COMPANY, 2010-MARCH 2012 (NO.) 101

CHAPTER 9 CURRENT SITUATION 105

MARKET TRENDS 105

SYNDROMES OF DEMENTIA 105

Market Drivers 106

MOVEMENT DISORDER SYNDROMES 107

Market Drivers 108

OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS 108

OTHER FACTORS AFFECTING THE MARKET 109

COLLABORATIONS/MERGERS AND ACQUISITIONS 109

CHAPTER 10 COMPANY PROFILES 113

ABBOTT LABORATORIES 113

ABLYNX NV 113

ACCERA INC. 114

ACORDA THERAPEUTICS INC. 115

ACTAVIS ELIZABETH 115

AFFIRIS AG 116

ALLIANCE PHARMA PLC 116

ALLON THERAPEUTICS INC. 116

ALPHAPHARM 117

ALZHYME LTD. 117

AMERICAN REGENT INC. 118

APOTEX INC. 118

APOTHECA INC. 119

ASTELLAS PHARMA INC. 119

ASTRAZENECA GMBH 120

AUROBINDO PHARMA LTD. 120

BAXTER INTERNATIONAL INC. 121

BELLUS HEALTH INC. 121

BOEHRINGER INGELHEIM LTD. 122

BRISTOL-MYERS SQUIBB 123

BRYANT RANCH PREPACK 123

CADILA HEALTHCARE LTD. 124

CARACO PHARMACEUTICAL LABORATORIES 124

CARDINAL HEALTH 125

CELLZOME AG 125

CIPLA LTD. 126

COGNITION THERAPEUTICS INC. 126

COLUCID PHARMACEUTICALS INC. 126

COMENTIS INC. 127

CORTEX PHARMACEUTICALS 127

CYTOS BIOTECHNOLOGY AG 128

DAIICHI SANKYO CO. LTD. 128

DR. REDDY'S LABORATORIES LTD. 129

EISAI CO. LTD. 129

ELAN PHARMA INTERNATIONAL LTD. 130

ELI LILLY AND CO. 130

ENDO PHARMACEUTICALS INC. 131

ENVIVO PHARMACEUTICALS 132

EVOTEC AG 132

EPITOMICS INC. 133

EXONHIT THERAPEUTICS SA 133

FOREST LABORATORIES INC. 134

GLAXOSMITHKLINE PLC 134

GLENMARK GENERICS LTD. 135

H. LUNDBECK A/S 136

HAMELN PHARMACEUTICALS LTD. 137

HELICON THERAPEUTICS INC. 137

HOSPIRA INC. 137

INTELLECT NEUROSCIENCES INC. 138

INTRA-CELLULAR THERAPIES INC. 138

JAZZ PHARMACEUTICALS PLC 139

MAJOR PHARMACEUTICALS 139

MEDIVATION INC. 140

MEMORY PHARMACEUTICALS CORP. 140

MERCK SERONO 140

MERCK SHARP & DOHME LTD. 141

MERZ PHARMA GMBH & CO KGAA 141

MITHRIDION INC. 142

MYLAN PHARMACEUTICALS 142

NEUREN PHARMACEUTICALS LTD. 143

NEURO-HITECH INC. 144

NEUROPTIX CORP. 144

NEUROSEARCH A/S 145

NEWRON PHARMACEUTICALS SPA 146

NOSCIRA SA 146

NOVARTIS AG 147

NYMOX PHARMACEUTICAL CORP. 147

ORCHID CHEMICALS & PHARMACEUTICALS LTD. 148

ORION CORP. 148

ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC. 149

PAR PHARMACEUTICALS 149

PERRIGO CO. 150

PFIZER INC. 150

PHARNEXT 151

PHYSICIANS TOTAL CARE INC. 152

PLIVA HRVATSKA D.O.O. 152

PRASCO LABORATORIES 153

RANBAXY LABORATORIES LTD. 153

ROCHE HOLDING LTD. 154

ROXANE LABORATORIES INC. 154

SANDOZ INTERNATIONAL GMBH 155

SANOFI 155

SANTHERA PHARMACEUTICALS 156

SHIONOGI & CO. 157

STADA ARZNEIMITTEL AG 157

SUN PHARMA 158

TAJ PHARMACEUTICALS LTD. 158

TAKEDA PHARMACEUTICAL CO. LTD. 159

TERCICA INC. 160

TEVA PHARMACEUTICAL INDUSTRIES LTD. 160

TORRENT PHARMA 161

UCB SA 162

UDL LABORATORIES 162

UPSHER-SMITH LABORATORIES 163

VALEANT PHARMACEUTICALS 163

VERNALIS PLC 164

WATSON PHARMACEUTICALS INC. 164

WEST-WARD PHARMACEUTICAL 165

CHAPTER 11 APPENDIX I: ABBREVIATIONS 168

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 6

TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY

PRIMARY CLINICAL/PATHOLOGICAL FEATURE 11

TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012 20

TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS 22

TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012 22

TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, 2010 TO MARCH 2012 23

TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, 2012 25

TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, 2011 30

TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS, 2010 39

TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 46

TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT

NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47

TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR

NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS) 50

TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%) 51

TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS) 53

TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54

TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 56

TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57

TABLE 17 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S

DISEASE 61

TABLE 18 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 ($

MILLIONS)

62

TABLE 19 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63

TABLE 20 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 ($ MILLIONS) 65

TABLE 21 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66

TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE BY

REGION, THROUGH 2017 ($ MILLIONS) 67

TABLE 23 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC

DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68

TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 ($

MILLIONS)

73

TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74

TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT

HUNTINGTONâ??S DISEASE 75

TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO

TREAT HUNTINGTON'S DISEASE, 2011 (%) 78

TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT

HUNTINGTON'S DISEASE 79

TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO

TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81

TABLE 30 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.) 85

TABLE 31 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86

TABLE 32 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.) 87

TABLE 33 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY

DISEASE TYPE, 2010-MARCH 2012 (NO.) 89

TABLE 34 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 90

TABLE 35 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY

PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 91

TABLE 36 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY

PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 92

TABLE 37 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER

SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 94

TABLE 38 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.) 96

TABLE 39 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY

COMPANY, 2010-MARCH 2012 (NO.) 101

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 6

FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 47

FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT

NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47

FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR

NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS) 50

FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%) 52

FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS) 53

FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54

FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 56

FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57

FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 ($

MILLIONS)

63

FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63

FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 ($ MILLIONS) 65

FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66

FIGURE 13 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY REGION,

2010-2017 ($ MILLIONS) 67

FIGURE 14 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC

DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68

FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA

WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 74

FIGURE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74

FIGURE 17 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR

USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%) 79

FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT

CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81

FIGURE 19 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.) 85

FIGURE 20 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF

DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%) 86

FIGURE 21 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND

MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86

FIGURE 22 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY

CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.) 88

FIGURE 23 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89

FIGURE 24 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA

(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 91

FIGURE 25 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES

BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 93

To order this report:

Pathology Industry: Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.